In research settings, similar observations have been reported, but responses vary by subject
Ozempic, Wegovy, and Zepbound Lead Surge Glucagon-like peptide-1 (GLP-1) receptor agonist drugs, represented by the obesity treatment Wegovy, are expected to achieve the highest global sales this year
Predicting antipsychotic-induced weight gain in first episode psychosis - A field-wide systematic review and meta-analysis of non-genetic prognostic factors
With a rapidly increasing number of GLP-1 drugs already being prescribed for conditions such as type 2 diabetes, obesity and kidney disease, these results suggest these medications could potentially be repurposed to reduce the risk of no-reflow in heart attack patients
However, these findings remain exploratory and non-clinical
the other is known mainly through harm reports attached to an unregulated product